Heart attack survivors: could a new shot clear your clogged arteries?

NCT ID NCT06372925

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests if a drug called inclisiran can reduce fatty plaque buildup in the arteries of people who recently had a heart attack and have high cholesterol. About 318 adults will receive either inclisiran or standard care, and doctors will use special imaging to measure plaque changes over one year. The goal is to see if this treatment can help control heart disease and prevent future problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    Hefei, Anhui, 230001, China

  • Novartis Investigative Site

    Fuzhou, Fujian, 350001, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510000, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510080, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, 518000, China

  • Novartis Investigative Site

    Zunyi, Guizhou, 563000, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, 150086, China

  • Novartis Investigative Site

    Zhengzhou, Henan, 450003, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430060, China

  • Novartis Investigative Site

    Nanchang, Jiangxi, 330006, China

  • Novartis Investigative Site

    Changchun, Jilin, 130033, China

  • Novartis Investigative Site

    Dalian, Liaoning, 116023, China

  • Novartis Investigative Site

    Jining, Shandong, 272000, China

  • Novartis Investigative Site

    Xian, Shanxi, 710061, China

  • Novartis Investigative Site

    Chengdu, Sichuan, 610072, China

  • Novartis Investigative Site

    Wenzhou, Zhejiang, 325027, China

  • Novartis Investigative Site

    Beijing, 101149, China

  • Novartis Investigative Site

    Lanzhou, 730000, China

  • Novartis Investigative Site

    Tianjin, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.